KEYNOTE-355: Final results from a randomized, doubleblind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC
KEYNOTE-355: Final results from a randomized, doubleblind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC
Cortés Castán, Javier; Cescon, D. W.; Rugo, H. S.; Im, S. A.; Yuso, M. Md.; Gallardo, C.; Lipatov, O.; Barrios, C. H.; Pérez García, José Manuel; Schmid, P.; Et al.